BACKGROUND: Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are major drivers of inflammation in multiple sclerosis. We aimed to determine the dose-response relationship between tolebrutinib and the reduction in new active brain MRI lesions in patients with relapsing multiple sclerosis. METHODS: We did a 16-week, phase 2b, randomised, double-blind, placebo-controlled, crossover, dose-finding trial at 40 centres (academic sites, specialty clinics, and general neurology centres) in ten countries in Europe and North America. Eligible participants were adults aged 18-55 years with diagnosed relapsing multiple sclerosis (either relapsing-remitting or relapsing secondary progressive multiple sclerosis), and one or more of the following criteria: at least one relapse within the previous year, at least two relapses within the previous 2 years, or at least one active gadolinium-enhancing brain lesion in the 6 months before screening. Exclusion criteria included a diagnosis of primary progressive multiple sclerosis or a diagnosis of secondary progressive multiple sclerosis without relapse. We used a two-step randomisation process to randomly assign eligible participants (1:1) to two cohorts, then further randomly assign participants in each cohort (1:1:1:1) to four tolebrutinib dose groups (5, 15, 30, and 60 mg administered once daily as an oral tablet). Cohort 1 received tolebrutinib for 12 weeks, then matched placebo (ie, identical looking tablets) for 4 weeks; cohort 2 received 4 weeks of placebo followed by 12 weeks of tolebrutinib. Participants and investigators were masked for dose and tolebrutinib-placebo administration sequence; investigators, study team members, and study participants did not have access to unmasked data. MRI scans were done at screening and every 4 weeks over 16 weeks. The primary efficacy endpoint was the number of new gadolinium-enhancing lesions detected on the scan done after 12 weeks of tolebrutinib treatment (assessed at week 12 for cohort 1 and week 16 for cohort 2), relative to the scan done 4 weeks previously, and compared with the lesions accumulated during 4 weeks of placebo run-in period in cohort 2. Efficacy data were analysed in a modified intention-to-treat population, using a two-step multiple comparison procedure with modelling analysis. Safety was assessed for all participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov (NCT03889639), EudraCT (2018-003927-12), and WHO (U1111-1220-0572), and has been completed. FINDINGS: Between May 14, 2019, and Jan 2, 2020, we enrolled and randomly assigned 130 participants to tolebrutinib: 33 to 5 mg, 32 to 15 mg, 33 to 30 mg, and 32 to 60 mg. 129 (99%) completed the treatment regimen and 126 were included in the primary analysis. At treatment week 12, there was a dose-dependent reduction in the number of new gadolinium-enhancing lesions (mean [SD] lesions per patient: placebo, 1·03 [2·50]; 5 mg, 1·39 [3·20]; 15 mg, 0·77 [1·48]; 30 mg, 0·76 [3·31]; 60 mg, 0·13 [0·43]; p=0·03). One serious adverse event was reported (one patient in the 60 mg group was admitted to hospital because of a multiple sclerosis relapse). The most common non-serious adverse event during tolebrutinib treatment was headache (in one [3%] of 33 in the 5 mg group; three [9%] of 32 in the 15 mg group; one [3%] of 33 in the 30 mg group; and four [13%] of 32 in the 60 mg group). No safety-related discontinuations or treatment-related deaths occurred. INTERPRETATION: 12 weeks of tolebrutinib treatment led to a dose-dependent reduction in new gadolinium-enhancing lesions, the 60 mg dose being the most efficacious, and the drug was well tolerated. Reduction of acute inflammation, combined with the potential to modulate the immune response within the CNS, provides a scientific rationale to pursue phase 3 clinical trials of tolebrutinib in patients with relapsing and progressive forms of multiple sclerosis. FUNDING: Sanofi.

Center for Neuroinflammation and Neurotherapeutics and the Department of Neurology University of Pennsylvania Philadelphia PA USA

Department of Medicine University of British Columbia Vancouver BC Canada

Department of Neurology Pardubice Regional Hospital Pardubice Czech Republic

Lille Neuroscience et Cognition University Lille INSERM UMR S1172 CHU Lille FHU Imminent Lille France

MellenCenter for Multiple Sclerosis Cleveland Clinic Cleveland OH USA

NeuroRx Research and Montréal Neurological Institute McGill University Montréal QC Canada

Republican Clinical Neurological Center Kazan Russia

Sanofi Cambridge MA USA

Translational Neuroradiology Section National Institute of Neurological Disorders and Stroke Bethesda MD USA

Lancet Neurol. 2021 Sep;20(9):689-691. doi: 10.1016/S1474-4422(21)00250-7. PubMed

Mult Scler Relat Disord. 2023 Sep;77:104850. doi: 10.1016/j.msard.2023.104850. PubMed

Zobrazit více v PubMed

Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. The New England journal of medicine 2018; 378(2): 169–80. PubMed PMC

Hauser SL, Bar-Or A, Cohen JA, et al.Ofatumumab versus Teriflunomide in Multiple Sclerosis. The New England journal of medicine 2020; 383(6): 546–57. PubMed

Hauser SL, Bar-Or A, Comi G, et al.Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. The New England journal of medicine 2017; 376(3): 221–34. PubMed

Montalban X, Arnold DL, Weber MS, et al.Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. The New England journal of medicine 2019; 380(25): 2406–17. PubMed

Bunai T, Terada T, Kono S, et al.Neuroinflammation following disease modifying therapy in multiple sclerosis: A pilot positron emission tomography study. J Neurol Sci 2018; 385: 30–3. PubMed

Datta G, Colasanti A, Rabiner EA, et al.Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. Brain 2017; 140(11): 2927–38. PubMed

Elliott C, Wolinsky JS, Hauser SL, et al.Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. Multiple sclerosis (Houndmills, Basingstoke, England) 2019; 25(14): 1915–25. PubMed PMC

Hendriks RW. Drug discovery: New Btk inhibitor holds promise. Nature chemical biology 2011; 7(1): 4–5. PubMed

Liang C, Tian D, Ren X, et al.The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review. Eur J Med Chem 2018; 151: 315–26. PubMed

Torke S, Pretzsch R, Hausler D, et al.Inhibition of Bruton’s tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease. Acta Neuropathol 2020; 140(4): 535–48. PubMed PMC

Weber ANR, Bittner Z, Liu X, Dang TM, Radsak MP, Brunner C. Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity. Front Immunol 2017; 8: 1454. PubMed PMC

Ghajarzadeh M, Azimi A, Valizadeh Z, Sahraian MA, Mohammadifar M. Efficacy and safety of rituximab in treating patients with multiple sclerosis (MS): A systematic review and meta-analysis. Autoimmun Rev 2020; 19(8): 102585. PubMed

Kappos L, Li D, Calabresi PA, et al.Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (London, England) 2011; 378(9805): 1779–87. PubMed

Montalban X, Hauser SL, Kappos L, et al.Ocrelizumab versus placebo in primary progressive multiple sclerosis. The New England journal of medicine 2017; 376(3): 209–20. PubMed

Keaney J, Gasser J, Gillet G, Scholz D, Kadiu I. Inhibition of Bruton’s Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer’s Disease. J Neuroimmune Pharmacol 2019; 14(3): 448–61. PubMed PMC

Magliozzi R, Howell O, Vora A, et al.Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130(Pt 4): 1089–104. PubMed

Zrzavy T, Hametner S, Wimmer I, Butovsky O, Weiner HL, Lassmann H. Loss of ‘homeostatic’ microglia and patterns of their activation in active multiple sclerosis. Brain 2017; 140(7): 1900–13. PubMed PMC

Francesco M, Wong M, LaStant J, et al.PRN2246, a potent and selective blood brain barrier penetrating BTK inhibitor, exhibits efficacy in central nervous system immunity. Multiple sclerosis (Houndmills, Basingstoke, England) 2017; 23(Issue 3_suppl): P989.

Smith P, Redfern J, Shu J, et al.Phase 1 clinical trial of PRN2246 (SAR442168), a covalent BTK inhibitor demonstrates safety, CNS exposure and therapeutic levels of BTK occupancy. Multiple sclerosis (Houndmills, Basingstoke, England) 2019; 25(Issue 1_suppl): P072.

Sormani MP, Bruzzi P. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials. The Lancet Neurology 2013; 12(7): 669–76. PubMed

Absinta M, Sati P, Schindler M, et al.Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest 2016; 126(7): 2597–609. PubMed PMC

Jackle K, Zeis T, Schaeren-Wiemers N, et al.Molecular signature of slowly expanding lesions in progressive multiple sclerosis. Brain 2020; 143(7): 2073–88. PubMed

Absinta M, Sati P, Masuzzo F, et al.Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. JAMA Neurol 2019; 76(12): 1474–83. PubMed PMC

Elliott C, Belachew S, Wolinsky JS, et al.Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. Brain 2019; 142(9): 2787–99. PubMed PMC

Lublin FD, Reingold SC, Cohen JA, et al.Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83(3): 278–86. PubMed PMC

Thompson AJ, Banwell BL, Barkhof F, et al.Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology 2018; 17(2): 162–73. PubMed

Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ, International Advisory Committee on Clinical Trials in MS. The 2013 clinical course descriptors for multiple sclerosis: A clarification. Neurology 2020; 94(24): 1088–92. PubMed PMC

Elliott C, Arnold DL, Collins DL, Arbel T. Temporally consistent probabilistic detection of new multiple sclerosis lesions in brain MRI. IEEE Trans Med Imaging 2013; 32(8): 1490–503. PubMed

Schofield MA, Zhu Y. Fast phase unwrapping algorithm for interferometric applications. Opt Lett 2003; 28(14): 1194–6. PubMed

Selmaj K, Li DK, Hartung HP, et al.Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. The Lancet Neurology 2013; 12(8): 756–67. PubMed

Miller DH, Khan OA, Sheremata WA, et al.A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348(1): 15–23. PubMed

Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology 2010; 75(4): 302–9. PubMed

Dal-Bianco A, Grabner G, Kronnerwetter C, et al.Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol 2017; 133(1): 25–42. PubMed PMC

A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis

Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review

Bioavailable central nervous system disease-modifying therapies for multiple sclerosis

B cell targeted therapies in inflammatory autoimmune disease of the central nervous system

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03889639

EudraCT
2018-003927-12